TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
4DMedical Ltd ( (AU:4DX) ) has shared an update.
4DMedical Limited has announced a significant expansion of its distribution agreement with Philips, which will now include the CT:VQ™ technology in its North American product catalogue. This deal, valued at approximately US$10 million over two years, marks a major commercial milestone for 4DMedical, as it leverages Philips’ extensive network to distribute its innovative imaging solution across the United States and Canada. The CT:VQ™ technology offers a superior alternative to traditional nuclear VQ imaging by eliminating the need for radiotracers, thereby streamlining patient access and improving diagnostic capabilities. With over one million nuclear VQ scans performed annually in the U.S., 4DMedical is poised to capture a significant portion of this market, potentially displacing traditional methods entirely.
The most recent analyst rating on (AU:4DX) stock is a Hold with a A$1.50 price target. To see the full list of analyst forecasts on 4DMedical Ltd stock, see the AU:4DX Stock Forecast page.
More about 4DMedical Ltd
4DMedical Limited is a global leader in respiratory imaging technology, specializing in advanced pulmonary diagnostics. The company focuses on developing innovative imaging solutions, such as the CT:VQ™, which provides non-contrast CT ventilation and perfusion imaging. 4DMedical aims to enhance patient outcomes and expand access to advanced diagnostic tools across the healthcare industry.
Average Trading Volume: 7,792,000
Technical Sentiment Signal: Buy
Current Market Cap: A$900.5M
For an in-depth examination of 4DX stock, go to TipRanks’ Overview page.